News for Neuronetics, Inc. (STIM)

New national awareness day will foster greater understanding of transcranial magnetic stimulation (TMS) treatment The company will celebrate on social media, sh

Neuronetics (STIM) launches National TMS Therapy Awareness Day on May 14, aligning with Mental Health Awareness Month. TMS, a non-drug treatment option

MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., ( STIM) (the ”œCompany” or ”œNeuronetics”) a vertically integrated, commercial stage,

**media[581340]**

Neuronetics' strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth. See why STIM stock is a promising investment.

**media[578950]**

The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Total Revenue: $22.5 million, an increase of 11% over the fourth quarter of 2023.NeuroStar System Revenue: $3.8 million with 46 systems shipped.U.S. Treatment

Mar 04, 2025 / 01:30PM GMTOperator Good day and thank you for standing by. Welcome to the Neuronetics fourth-quarter 2024 financial and operating results confer

Neuronetics, Inc. (NASDAQ:STIM) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ETCompany ParticipantsMark Klausner - Investor RelationsKeith...

Neuronetics, Inc. (STIM), Tuesday announced financial outlook for the first quarter and fiscal year 2025. The company sees worldwide revenue between $28.0 million and $30.

MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM) (the ”œCompany” or ”œNeuronetics”) a vertically integrated, commercial stage,

**media[556688]**

Revenue: Achieved $22.5 million in Q4 2024, surpassing the estimated $19.63 million and marking an 11% increase from Q4 2023.Earnings Per Share (EPS): Reported

Neuronetics (STIM) Q4 results: GAAP EPS misses by $0.09; revenue rises 10.7%. 2025 outlook: $145M-$155M revenue, 55% gross margin.

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. ( STIM), a commercial stage medical technology company focused on designing, developing, an

**media[556115]**

Neuronetics Inc (STIM) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $19.63 million, and the earnings are

**media[535348]**